Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 3,348 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total value of $67,361.76. Following the completion of the transaction, the chief accounting officer now directly owns 63,654 shares of the company's stock, valued at $1,280,718.48. This trade represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Sandra Calvin also recently made the following trade(s):
- On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.94, for a total transaction of $17,519.50.
- On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
- On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00.
Travere Therapeutics Price Performance
Shares of NASDAQ:TVTX traded down $0.11 on Friday, hitting $21.75. The company had a trading volume of 2,442,302 shares, compared to its average volume of 1,303,585. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.70 billion, a PE ratio of -4.78 and a beta of 0.72. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $22.25. The business has a 50 day moving average of $18.86 and a 200 day moving average of $15.64.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth about $217,000. Arizona State Retirement System grew its stake in Travere Therapeutics by 13.5% in the 4th quarter. Arizona State Retirement System now owns 22,396 shares of the company's stock worth $390,000 after acquiring an additional 2,666 shares during the period. Aigen Investment Management LP grew its stake in Travere Therapeutics by 56.6% in the 4th quarter. Aigen Investment Management LP now owns 19,072 shares of the company's stock worth $332,000 after acquiring an additional 6,892 shares during the period. Victory Capital Management Inc. acquired a new position in Travere Therapeutics in the 4th quarter valued at $182,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Travere Therapeutics by 16.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company's stock worth $11,525,000 after purchasing an additional 94,194 shares during the period.
Analyst Upgrades and Downgrades
TVTX has been the subject of several research analyst reports. HC Wainwright increased their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, January 15th. Wells Fargo & Company raised shares of Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $9.00 to $27.00 in a report on Monday, October 21st. Scotiabank boosted their price target on Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on Travere Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating for the company. Finally, Barclays lifted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.00.
Read Our Latest Report on TVTX
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Featured Articles
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
